长链非编码RNAH19在甲状腺癌中的表达及预后预测的研究
2018-09-03刘娜乞艳华周琦
刘娜 乞艳华 周琦
[摘要] 目的 探討长链非编码RNA H19(lncRNA H19)在甲状腺癌中的表达情况及其与临床病理特征和预后的相关性,寻找影响甲状腺癌治疗及预后的新靶点。 方法 选取2009年1月~2012年1月从西安交大第二附属医院搜集的131例甲状腺癌组织和癌旁组织为病例组,另外同期选取122例甲状腺良性肿瘤组织作为对照组。采用实时定量聚合酶链反应(qRT-PCR)方法检测lncRNA H19的表达情况。之后进行5年跟踪随访。通过受试者工作特征(ROC)曲线分析评估lncRNA H19对甲状腺癌的诊断价值。应用Kaplan-Meier方法计算5年累积生存率,预后相关单因素分析采用Log-rank检验,多因素分析采用Cox回归模型。 结果 与甲状腺良性肿瘤组织及癌旁组织比较,甲状腺癌组织中lncRNA H19表达升高(P < 0.05)。lncRNA H19诊断甲状腺癌ROC曲线下面积(AUC)为0.801,诊断阈值3.58,敏感度和特异度分别为72.5%和75.4%,约登指数0.479。肿瘤直径≥1 cm、TNM Ⅲ+Ⅳ期及有淋巴结转移的甲状腺癌组织中lnc RNA H19表达水平明显高于肿瘤直径<1 cm、TNM Ⅰ+Ⅱ期及无淋巴结转移的甲状腺癌组织,差异均有统计学意义(P < 0.05)。lncRNA H19高表达者5年生存率下降(28.44%)。lncRNA H19表达水平、肿瘤直径、TNM分期和淋巴结转移是影响甲状腺癌预后的独立风险因素。 结论 lncRNA H19在甲状腺癌组织中高表达,lncRNA H19表达水平上调与甲状腺癌预后差相关,提示其可能是甲状腺癌发生发展的分子调节机制之一,并可为甲状腺癌早期无创诊断及治疗靶点的寻找提供重要理论依据。
[关键词] 甲状腺癌;长链非编码RNAs;长链非编码RNA H19;预后
[中图分类号] R736.1 [文献标识码] A [文章编号] 1673-7210(2018)05(a)-0025-06
Expression status and prognostic significance of lncRNA H19 in thyroid carcinoma
LIU Na1 QI Yanhua1 ZHOU Qi1 CHENG Chuantao2 YANG Wenbin2
1.Department of Ultrasound, the Second Affiliated Hospital of Xi′an Jiao Tong University, Shaanxi Province, Xi′an 710004, China; 2.Department of General Surgery, the Second Affiliated Hospital of Xi′an Jiao Tong University, Shaanxi Province, Xi′an 710004, China
[Abstract] Objective To explore the expression of long non-coding RNA H19 (lncRNA H19) in thyroid carcinoma (TC), and its correlation with the clinicopathologic characteristics and prognosis of TC. Methods From January 2009 to January 2012, 131 TC tissues and adjacent tissues were collected from patients after thyroid surgery between as case group. Concurrently, additional 122 normal thyroid tissues from patients with benign thyroid lesions were obtained as normal control group. The expression level of lncRNA H19 were detected by quantitative real-time PCR (qRT-PCR). five years follow-ups were conducted. Receiver operating curve(ROC) was used to evaluate the diagnostic values of lncRNA H19 for TC. The Kaplan-Meier method were employed to analyze 5-year survival rate of TC patient. Both univariate and multivariate analyses were performed to analyze the prognostic factors of TC. Results The lncRNA H19 expression was higher in TC tissues than that in the adjacent and normal tissues(P < 0.05). The area under the ROC curve(AUC) of lncRNA H19 were 0.801. Diagnostic boundary point was 3.58. Sensitivity and specificity was 72.5% and 75.4% respectively. Youden index was 0.479. The lncRNA H19 expression in TC tissue with tumor diameter no less than 1 cm, TNM Ⅲ+Ⅳ stage, or lymph node metastasis was evidently higher than that in TC tissue with tumor smaller than 1 cm, TNM Ⅰ+Ⅱ stage, or without lymph node metastasis(P < 0.05). The 5-year survival rate of TC patients with high lncRNA H19 expression declined (28.44%). The expression of lncRNA H19, tumor diameter, TNM stage and lymph node metastasis were independent prognostic factors of TC patients (P < 0.05). Conclusion The increased lncRNA H19 expression levels are associated with clinicopathologic characteristics and poor prognosis in TC patients. And it may be one of the molecular regulation mechanism in TC occurrence and development. This study also can provide basis for noninvasive diagnosis and therapeutic target searching in TC.
[Key words] Thyroid carcinoma; Long non-coding RNAs; lncRNA H19; Prognosis
甲状腺癌是最常见的内分泌恶性肿瘤,且30年来,发病率逐渐增高,目前统计我国甲状腺癌的发病率和病死率分别为0.32%和0.03%[1]。甲状腺乳头状癌是主要的病理类型,占所有甲状腺恶性肿瘤的86%[2]。甲状腺癌根治术是目前治疗甲状腺癌的主要方式,虽然绝大多数患者手术切除后有很好的总体生存率,但也有部分患者手术治疗后预后差。甲状腺癌的侵袭特征、发生机制尚不明确,分子调控机制是一个新的思路。一个理想的生物标志物有助于早期诊断甲状腺癌,判断其预后情况。lncRNAs(long non-coding RNAs)一般是指大于200个核苷酸,缺少为蛋白质编码功能的RNA[3]。已有证据表明lncRNAs与多种恶性肿瘤的发生、迁移、凋亡过程相关[4]。……
